Adamis Pharmaceuticals Corp - FORM 10-K - EX-23.1 - CONSENT OF MAYER HOFFMAN MCCANN P.C. - March 30, 2017

Attached files

file filename
EX-10.64 - SEPTEMBER 2016 AMENDMENT TO COMMERCIAL LINE OF CREDIT AGREEMENT AND NOTE - Adamis Pharmaceuticals Corpex10-64.htm
EX-32.2 - CERTIFICATION BY CFO - Adamis Pharmaceuticals Corpex32-2.htm
EX-32.1 - CERTIFICATION BY CEO - Adamis Pharmaceuticals Corpex32-1.htm
EX-31.2 - CERTIFICATION BY CFO - Adamis Pharmaceuticals Corpex31-2.htm
EX-31.1 - CERTIFICATION BY CEO - Adamis Pharmaceuticals Corpex31-1.htm
EX-23.2 - CONSENT OF HUDSON CISNE & CO., LLP - Adamis Pharmaceuticals Corpex23-2.htm
EX-21.1 - SUBSIDIARIES - Adamis Pharmaceuticals Corpex21-1.htm
EX-10.85 - MARCH 2017 AMENDMENT TO LOAN AND SECURITY AGREEMENT - Adamis Pharmaceuticals Corpex10-85.htm
EX-10.84 - MARCH 2017 AMENDED AND RESTATED LINE OF CREDIT PROMISSORY NOTE - Adamis Pharmaceuticals Corpex10-84.htm
EX-10.83 - EXECUTIVE EMPLOYMENT AGREEMENT - Adamis Pharmaceuticals Corpex10-83.htm
EX-10.81 - EXECUTIVE EMPLOYMENT AGREEMENT - Adamis Pharmaceuticals Corpex10-81.htm
EX-10.80 - BONUS PLAN - Adamis Pharmaceuticals Corpex10-80.htm
EX-10.65 - LOAN RELEASE AGREEMENT DATED AS OF NOVEMBER 14, 2016 - Adamis Pharmaceuticals Corpex10-65.htm
EX-10.63 - AMENDMENT TO LOAN AGREEMENT - Adamis Pharmaceuticals Corpex10-63.htm
EX-10.62 - SEPTEMBER 2016 LOAN AMENDMENT AND CONSOLIDATION AGREEMENT AMONG BEAR STATE BANK, - Adamis Pharmaceuticals Corpex10-62.htm
EX-10.61 - LOAN AMENDMENT AND ASSUMPTION AGREEMENT DATED AS OF NOVEMBER 3, 2016 - Adamis Pharmaceuticals Corpex10-61.htm
EX-10.4 - RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND AWARD AGREEMENT - Adamis Pharmaceuticals Corpex10-4.htm
10-K - ANNUAL REPORT - Adamis Pharmaceuticals Corpadmp_10k-123116.htm
 

ADAMIS PHARMACEUTICALS CORPORATION 10-K

 

 

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We hereby consent to the incorporation by reference in the Prospectus constituting a part of the Registration Statements on Form S-8 (Nos. 333-159229, 333-169106, 333-175383, 333-196435, 333-201742 and 333-211773), on Form S-1 (Nos. 333-190798, 333-192372, and 333- 192801), and on Form S-3 (Nos. 333-196976, 333-199454, 333-200447, 333-209401 and 333-212880) of our report dated March 30, 2017, (which includes an explanatory paragraph relating to the uncertainty of the Company’s ability to continue as a going concern) relating to the consolidated financial statements of Adamis Pharmaceuticals Corporation and Subsidiaries (the Company), as of and for the periods ended December 31, 2016 and December 31, 2015, which report is included in this Annual Report on Form 10-K.

 

/s/ MAYER HOFFMAN MCCANN P.C.

San Diego, California

March 30, 2017

 

 

 

Stock widget

Investing forum

Adamis Pharmaceuticals Corp Reports